Activity Description
The focus of this fourth and final installment of the educational series on Macular Telangiectasia Type 2 (MacTel) is on patient-centered communication, surgical considerations, and long-term follow-up. TFG’s expert consensus group reviewed a typical patient’s presentation, including preserved visual acuity with significant quality-of-life impairment such as slowed reading speed, metamorphopsia, paracentral scotomas, and driving challenges. This installment explores how clinicians can translate structural imaging findings into language patients understand, helping them recognize the functional implications of a slowly progressive neurodegenerative disease.
The consensus group emphasizes informed consent, expectations management, and the importance of clarifying that neuroprotective therapies are designed to slow progression, not restore lost vision. Surgical considerations, risk-benefit assessment, and follow-up strategies are reviewed, particularly in determining the “sweet spot” for intervention before advanced atrophy limits therapeutic impact.
By the end of this program, clinicians will be better prepared to counsel patients effectively, align expectations with therapeutic goals, and support shared decision-making throughout the course of care.
The Fundingsland Group is accredited by the ACCME to provide continuing medical education for physicians.
Release Date: 4/30/26
Expiration Date: 4/30/27
Target Audience
This accredited educational activity is designed for ophthalmologists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from Neurotech.
Faculty
